0
Abstract: Slide Presentations |

PERFORMANCE OF PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) VS. LEFT VENTRICULAR END DIASTOLIC PRESSURE (LVEDP) IN THE DIAGNOSIS/CLASSIFICATION OF PATIENTS WITH SUSPECT PULMONARY ARTERIAL HYPERTENSION (PAH) FREE TO VIEW

Francisco J. Soto, MD*; Ronald Siegel, MD; David Marks, MD; James Kleczka, MD; Timothy Woods, MD; James P. Maloney, MD; Amina Syed, MD; Amjad Syed, MD; Sonika Gupta, MD; Kenneth Presberg, MD
Author and Funding Information

Medical College of Wisconsin, Milwaukee, WI


Chest


Chest. 2005;128(4_MeetingAbstracts):137S. doi:10.1378/chest.128.4_MeetingAbstracts.137S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  Some therapies - e.g. bosentan or prostacyclin- are only indicated and approved for PAH but not for pulmonary venous hypertension (PVH). A diagnosis of PAH implies a mean pulmonary arterial pressure (mPAP) >25 mmHg at rest and a normal left ventricular (LV) filling pressure (<15 mmHg) to exclude PVH. A PCWP <15 mmHg is generally assumed to exclude PVH but a rigorous comparison of PCWP with the “gold standard” LVEDP < 15 mmHg in patients with PAH is lacking. We hypothesized that sole reliance on PCWP might erroneously misclassify a significant number of patients with PVH as PAH.

METHODS:  We reviewed the records and raw catheterization data from 131 patients who underwent simultaneous right and left catheterization as part of their evaluation for suspected pulmonary hypertension (PH) and in whom PH was confirmed. The diagnostic performance of PCWP vs. LVEDP was evaluated using a 2 x 2 contingency table. A chi-square test was used to compare those results. Linear regression analysis was used for comparison of continuous variables.

RESULTS:  Our patients were 60 years of age, mostly women (76%) and predominantly white (75%). The most common etiologies of PH were collagen vascular disease (24%), LV diastolic dysfunction (20%) and idiopathic PAH (18%). LVEDP suggested PVH in 59% of patients vs. 37% by PCWP (p= <0.0001). Up to 37% of patients with PVH would have been misclassified as PAH by PCWP measurement alone.

CONCLUSION:  We report limitations to the use of PCWP as the only method of assessing LV filling pressures in patients with suspected PAH, especially when PCWP is >10. We found that LVEDP measurement was important to accurately differentiate between PAH and PVH.

CLINICAL IMPLICATIONS:  Since the current data support the benefit of certain therapies in PAH only, careful assessment of LV filling pressures is indicated before such therapies are initiated. PAH-specific therapies are not only expensive but can lead to higher morbidity and mortality when used in PVH.

DISCLOSURE:  Francisco Soto, None.

Monday, October 31, 2005

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543